1.Compliance and influence factors of standardized medication in patients with coronary artery disease
Yongcang HU ; Jianhua ZHANG ; Jiacai WANG ; Rongcheng LI ; Chao DING ; Yanyan CHEN ; Xiannan LI ; Yan XU
Chinese Journal of Primary Medicine and Pharmacy 2015;(10):1441-1443
Objective To evaluate the standardized drug treatment and its influence factors of patients,with coronary artery disease,in hospital and one year after discharge.Methods The study enrolled sequentially 165 patients who were firstly diagnosed of coronary artery disease,61 cases with stable angina,67 cases with unstable angi-na and 37 cases of acute myocardial infarction,by coronary artery angiography from 2010 to 2012.The standardized drug treatment and its influence factors of patients were analyzed at hospital and 1 year after discharge in the present study.Results Fifty five percent patients with coronary artery disease at hospital regularly took the four drugs,anti-platelet agents,statins,beta blockers and angiotensin converting enzyme inhibitors/angiotensin II receptor antagonist. The ratio decreased to forty five percent one year after discharge(χ2 =81.04,P <0.01).The reasons of the irregular medication taken were optional withdrawal(61%),following the doctors′advice(15%),economic hardship(20%) and the drugs′adverse reaction(4%).Conclusion The results of the present study showed that the rate of regular medication in patients with coronary artery disease is low in hospital and 1 year after discharge.The major reasons of the irregular medicine taken were the patients′optional withdrawal and the consciousness of second prevention was lack in doctors in our hospital.Therefore,the increase of the consciousness of regular standardized treatment in prima-ry care physicians and strengthen the management of the patients after discharge form hospital.
2.Research on the genotypes of clinical varicella-zoster virus isolates in Tibet
Lan LIU ; Baozhong DU ; Yongcang ZHANG ; Yaping DUAN ; Lin GAN ; Changshan LI
Chinese Journal of Microbiology and Immunology 2012;(11):934-938
Objective To analyze the genotypes of clinical varicella-zoster virus(VZV) isolates in Tibet.Methods The samples of vesicular fluid from patients with chickenpox or zoster were collected to isolate VZV in human embryonic fibroblast cells.Furtherly,the isolated VZV were identified by indirect immunofluorescence assay and the positive ones were continuely cultured in vitro to get their genome DNAs.Then,PCR and nucleotide sequencing were performed on the part of open reading frames 1,21,50,54.To confirm the genotypes of isolated virus strains,the gene sequences obtained from PCR products were compared with that in GenBank of VZV Dumas strains,and their restriction enzyme sites were analyzed via Primer 5.0.Results Ten clinical isolates of VZV were obtained from sixteen specimens,the positive isolation rate was 62.5%.Gene analysis showed that among all the ten clinical isolates of VZV in Tibet,three strains are genotype A1,four are genotype A2 and the other three are genotype J1.Conclusion The VZV genotype distribution in Tibet was tightly related to their special geographic locations.
3.EFFECT OF ANISODINE ON BRAIN MONOAMINE
Peigen KUANG ; Fulin DAI ; Xinfu ZHOU ; Bo XU ; Yongcang LI ; Fengying ZHANG
Medical Journal of Chinese People's Liberation Army 1982;0(01):-
The effect of anisodine on brain monoamine was studied in 30 rats. The brain monoamine levels of caudate nucleus, hippocampus, diencephalon, brain stem and cerebral cortex were estimated by fluoro-metric method in drug-treated rats and saline-treated controls. Only the NE level of the brain stem was significantly increased in anisodine-treated animals 48 hours after injection. There were no significant differences in the dopamine values between anisodine-treated rats and saline-treated controls, while the 5HT and 5HIAA levels were significantly increased in anisodine-treated animals. The relation of brain monoamines to learning and memory is discussed. The increased 5HT and 5HIAA levels caused by anisodine may play a role in the impairment of memory.
4.Experssion of human FGFR2IIIc and its S252W mutant in MDA-MB-231 breast cancer cells with adenovirus vectors.
Yongcang ZHANG ; Liling LI ; Xiaojia CHEN ; Li QIN ; Shujun GUO ; Lan LIU ; Lihui XU ; An HONG
Chinese Journal of Biotechnology 2010;26(3):363-370
To study the functions of human Fibroblast growth factor receptor 2IIIc (FGFR2IIIc) gene in cancer cells, breast cancer cells MDA-MB-231 were infected by recombinant adenoviruses containing FGFR2IIIc and its S252W mutant, respectively. FGFR2IIIc gene was amplified from an existing plasmid and its S252W mutant was obtained by overlapping extension PCR. These two genes were separately cloned into the adenoviral shuttle plasmid pAdTrack-CMV, confivmed by DNA sequencing linearized, and co-transformed into Escherichia coli BJ-5183 with the adenoviral vector pAdEasy-1. The resulting recombinant expression vectors Ad-FGFR2IIIc and Ad-FGFR2IIIcS252W were linearized and transfected into HEK293A cells to get adenoviral particles. GFP was used to verify the gene expression. The recombinant adenoviral particles were harvested, titrated, and then infected MDA-MB-231 cells. The expression of FGFR2IIIc and its S252W mutant were examined by RT-PCR and Western blotting, and the effect of these recombinant adenoviruses on MDA-MB-231 cell proliferation was analyzed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry. The results showed the recombinant adenoviral particles could infect MDA-MB-231 cells and express the target proteins. MTT showed that both FGFR2IIIc and its S252W mutant inhibited MDA-MB-231 cell proliferation, but the mutant was more effective. Flow cytometry showed that both FGFR2IIIc and its S252W mutant arrested MDA-MB-231 cell cycle at G0/G1 phase, resulting in low cell proliferation.
Adenoviridae
;
genetics
;
metabolism
;
Antineoplastic Agents
;
pharmacology
;
Breast Neoplasms
;
metabolism
;
pathology
;
Cell Line, Tumor
;
Female
;
Genetic Vectors
;
genetics
;
Humans
;
Mutant Proteins
;
biosynthesis
;
genetics
;
Receptor, Fibroblast Growth Factor, Type 2
;
biosynthesis
;
genetics
;
Recombinant Proteins
;
biosynthesis
;
genetics
;
pharmacology
;
Transfection